Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Hantao Lou"'
Autor:
Zhu Liang, Andreas Damianou, Iolanda Vendrell, Edward Jenkins, Frederik H. Lassen, Sam J. Washer, Athina Grigoriou, Guihai Liu, Gangshun Yi, Hantao Lou, Fangyuan Cao, Xiaonan Zheng, Ricardo A. Fernandes, Tao Dong, Edward W. Tate, Elena Di Daniel, Benedikt M. Kessler
Publikováno v:
Cell Reports, Vol 43, Iss 5, Pp 114152- (2024)
Summary: Activation of the NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome complex is an essential innate immune signaling mechanism. To reveal how human NLRP3 inflammasome assembly and activation are controlled, in particular b
Externí odkaz:
https://doaj.org/article/a5167cfa972c4f8d8edd1f27601d7520
Autor:
Houfu Leng, Hanlin Zhang, Linsen Li, Shuhao Zhang, Yanping Wang, Selina J. Chavda, Daria Galas-Filipowicz, Hantao Lou, Adel Ersek, Emma V. Morris, Erdinc Sezgin, Yi-Hsuan Lee, Yunsen Li, Ana Victoria Lechuga-Vieco, Mei Tian, Jian-Qing Mi, Kwee Yong, Qing Zhong, Claire M. Edwards, Anna Katharina Simon, Nicole J. Horwood
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-18 (2022)
Here, the authors show that the glycosylceramide synthesis inhibitor and FDA approved drug Eliglustat inhibits autophagic degradation of TRAF3 which is a key step for osteoclast differentiation and thereby improves myeloma bone lesions.
Externí odkaz:
https://doaj.org/article/d3f4b2b671d34e5f9416142c53caf80d
Autor:
Hantao Lou, Xuetao Cao
Publikováno v:
Cancer Communications, Vol 42, Iss 9, Pp 804-827 (2022)
Abstract The efficacy and specificity of conventional monoclonal antibody (mAb) drugs in the clinic require further improvement. Currently, the development and application of novel antibody formats for improving cancer immunotherapy have attracted mu
Externí odkaz:
https://doaj.org/article/09cf713f0c494214a401c94954571733
Autor:
Jingyi Ma, Al Moussawi, Khatoun, Hantao Lou, Hok Fung Chan, Yihua Wang, Chadwick, Joseph, Chansavath Phetsouphanh, Slee, Elizabeth A., Shan Zhong, Leissing, Thomas M., Roth, Andrew, Xiao Qin, Shuo Chen, Jie Yin, Ratnayaka, Indrika, Yang Hu, Louphrasitthiphol, Pakavarin, Taylor, Lewis, Bettencourt, Paulo J. G., Muers, Mary
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America; 3/5/2024, Vol. 121 Issue 10, p1-12, 51p
Autor:
Chloe S Palma Chaundler, Haonan Lu, Ruisi Fu, Ning Wang, Hantao Lou, Gilberto Serrano de Almeida, Layla Mohammad Hadi, Eric O Aboagye, Sadaf Ghaem-Maghami
Antibody-drug conjugates (ADCs) are emerging targeted agents against cancer. Current studies of ADCs are performed on monolayer cultures which do not mimic the biophysical property of a tumour. Hence,in vitromodels that can better predict the efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e498879a3b8286185dc6452406499f60
https://doi.org/10.1101/2023.02.14.528517
https://doi.org/10.1101/2023.02.14.528517
Autor:
Dongnan Yan, Haonan Lu, Apanpreet Kaur, Ruisi Fu, Ning Wang, Jin Hui Teh, Hantao Lou, Eric O Aboagye, Rongjun Chen
Messenger RNA (mRNA) has been proposed as a therapeutic agent for various diseases, including cancer. To ensure effective transfection of cancer cells, mRNA needs to be transported with a delivery system that protects its integrity and functionality.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16e70f7151847c7ea60f845f889729a2
https://doi.org/10.1101/2023.02.07.524134
https://doi.org/10.1101/2023.02.07.524134
Autor:
Ruisi Fu, Hantao Lou, Ning Wang, Dongnan Yan, Clara Tresserras-Segura, Haonan Lu, Eric Aboagye
Publikováno v:
Cancer Research. 83:455-455
Antibody drug conjugate (ADC) is a novel class of therapeutic agent which recently showed great success in both solid tumour and blood cancer. ADCs deliver potent cytotoxic payloads to tumour via cancer specific monoclonal antibodies. A few ADCs are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c937763fbaefbcaf36138a04bf0d607
https://doi.org/10.1158/1538-7445.am2023-455
https://doi.org/10.1158/1538-7445.am2023-455
Autor:
Haonan Lu, Georg Wengert, Hantao Lou, Reema Paudel, Naina Patel, Saral Desai, Bill Crum, Kristofer Linton-Reid, Mitchell Chen, Dongyang Li, Jacey Ip, Francesco Mauri, David J. Pinato, Andrea Rockall, Susan J. Copley, Sadaf Ghaem-Maghami, Eric O. Aboagye
Publikováno v:
Cancer Research. 83:600-600
Tertiary lymphoid structure (TLS) is an ectopic lymphoid organ found in some tumors. The presence of TLS is recently proposed as a predictive biomarker for immune checkpoint inhibitors (ICI) in mutation-driven tumors. It is also associated with progn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9937e69073fb8c3d7f3b73df0f668548
https://doi.org/10.1158/1538-7445.am2023-600
https://doi.org/10.1158/1538-7445.am2023-600
Publikováno v:
Journal of Autoimmunity. 132:102861
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ inflammatory damage and wide spectrum of autoantibodies. The autoantibodies, especially anti-dsDNA and anti-Sm autoantibodies are highly specific to SLE, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1ddb5d3f344e80693ab85ef6bd9b44a
https://doi.org/10.1016/j.jaut.2022.102861
https://doi.org/10.1016/j.jaut.2022.102861
Autor:
Thomas M. Carroll, Joseph A. Chadwick, Richard P. Owen, Michael J. White, Joseph Kaplinsky, Iliana Peneva, Anna Frangou, Jaeho Chang, Phil F. Xie, Andrew Roth, Bob Amess, Hantao Lou, Katy J. McCann, Georgina Berridge, Roman Fischer, Chansavath Phetsouphanh, Ayo O. Omiyale, Brittany-Amber Jacobs, David Ahern, Simon R. Lord, Stewart Norris-Bulpitt, Sam T. Dobbie, Lucinda Griffiths, Kristen Aufiero Ramirez, Toni Ricciardi, Mary J. Macri, Aileen Ryan, Ralph R. Venhaus, Benoit J. Van den Eynde, Ioannis Karydis, Benedikt M. Kessler, Benjamin Schuster-Böckler, Mark R. Middleton, Xin Lu
Publikováno v:
Cancer Research. 82:1247-1247
For patients with inoperable esophageal adenocarcinoma (EAC), prognosis on conventional chemotherapy (CTX) remains poor. In 2021, the FDA approved two αPD-1 immune checkpoint inhibitors (ICI) for addition to fluoropyrimidine/platinum-containing CTX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76f5d2641b1d59ef3c689eb7850e59cf
https://doi.org/10.1158/1538-7445.am2022-1247
https://doi.org/10.1158/1538-7445.am2022-1247